Onconetix, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
ONCO$3.47-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended | Three Months Ended | Six Months Ended | Six Months Ended | |
|---|---|---|---|---|
| June 30, 2025 | June 30, 2024 | June 30, 2025 | June 30, 2024 | |
| Revenue | $106,494 | $704,848 | $208,124 | $1,405,281 |
| Cost of revenue | 35,991 | 604,132 | 91,789 | 1,115,565 |
| Gross profit | 70,503 | 100,716 | 116,335 | 289,716 |
| Operating expenses | ||||
| Selling, general and administrative | 1,523,591 | 2,221,275 | 3,197,797 | 5,957,725 |
| Research and development | (111,670) | (3,680) | (87,215) | 45,284 |
| Impairment of ENTADFI assets | — | 1,237,140 | — | 3,530,716 |
| Impairment of goodwill | 594,000 | 10,261,000 | 11,512,000 | 15,453,000 |
| Total operating expenses | 2,005,921 | 13,715,735 | 14,622,582 | 24,986,725 |
| Loss from operations | (1,935,418) | (13,615,019) | (14,506,247) | (24,697,009) |
| Other (expense) income | ||||
| Interest expense - related party | — | (156,169) | — | (380,943) |
| Interest expense | (223,097) | (205,146) | (446,689) | (393,429) |
| Change in fair value of subscription agreement liability | (191,038) | (248,000) | 3,127,962 | (21,600) |
| Change in fair value of contingent warrant liabilities | (229) | — | (10,024) | — |
| Gain on forgiveness of accounts payable | — | — | 944,694 | — |
| Other loss | (22,660) | (31,602) | (28,023) | (3,094) |
| Total other (expense) income | (437,024) | (640,917) | 3,587,920 | (799,066) |
| Loss before income taxes | (2,372,442) | (14,255,936) | (10,918,327) | (25,496,075) |
| Income tax (expense) benefit | — | (50,768) | — | 70,799 |
| Net loss | $(2,372,442) | $(14,306,704) | $(10,918,327) | $(25,425,276) |
| Deemed dividend Series C preferred stock | (328,504) | — | (1,498,595) | — |
| Net loss applicable to common stockholders | (2,700,946) | (14,306,704) | (12,416,922) | (25,425,276) |
| Net loss per share, basic and diluted | $(4.76) | $(2,191.59) | $(31.67) | $(3,898.98) |
| Weighted average number of common shares outstanding, basic and diluted | 567,648 | 6,528 | 392,133 | 6,521 |
| Other comprehensive income (loss) | ||||
| Net loss | $(2,372,442) | $(14,306,704) | $(10,918,327) | $(25,425,276) |
| Foreign currency translation | 1,882,464 | 110,000 | 2,023,512 | (4,881,144) |
| Change in pension benefit obligation | 345,318 | (33,406) | 314,539 | 121,272 |
| Total comprehensive loss | $(144,660) | $(14,230,110) | $(8,580,276) | $(30,185,148) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.